Eli Lilly and Co. continues to pursue main infringement actions
against all generic companies marketing generic olanzapine
products in Germany, according to the Company’s latest Quarterly
Reports filed with the…
provides in-depth news coverage of intellectual property lawsuits involving public companies with assets of USD $1 billion or more. Coverage focuses on the infringement of intellectual property rights (including patents, copyrights, trademarks, trade dress, trade secrets, and royalties) and corporate indemnification of intellectual property violations.